TIL Therapy Holds Potential for Growth in Advanced Melanoma cancernetwork.com/view/til-thera… via @CancerNetwork® KU Cancer Center Mikael Rayaan Foundation USMIRC News OncoDaily

Having encountered a series of patients with hyperviscosity syndrome lately, came across this gem of a paper by Morie Gertz in Blood Journals Portfolio on acute hyperviscosity syndromes across plasma cell disorders (and more). It explains not only the clinical presentation/management but

Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series | Communications ⁦Nature Medicine⁩ ⁦مستشفى الملك فيصل التخصصي ومركز الأبحاث⁩ ⁦مركز الأبحاث⁩ The 1st case series... Proud of our team nature.com/articles/s4385…

Semaglutide and cagrilintide have each been shown to induce weight loss, but how these drugs work in combination in patients with type 2 diabetes and overweight or obesity is unknown. Research findings are summarized in a new Quick Take video. nej.md/4ozgv5s

TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care cancernetwork.com/view/til-thera… via CancerNetwork® KU Cancer Center USMIRC News Mikael Rayaan Foundation OncoDaily

Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy - ESMO Gastrointestinal Oncology esmogastro.org/article/S2949-…

#Myeloma Paper of the Day: Study of global burden & trends of myeloma due to obesity finds deaths due to high BMI increased from 3.00-9.20 thousand (1990-2021), DALYs rose from 72.00-207.60 thousand, age-standardized mortality rate & DALY increased: pubmed.ncbi.nlm.nih.gov/40813677/. #mmsm

Systematic review: Childhood #cancer survivorship research is concentrated in high-income countries, highlighting a need for broader global studies to ensure equitable outcomes for survivors. ja.ma/4mIlnDP Neel Bhatt Venky

Cool fireside chat b/w Joe and Shaji International Myeloma Foundation Joseph Mikhael

👉👉👉Please join us ! Co-founded by Ruben A. Mesa, MD & Naveen Pemmaraju, MD & our team for the upcoming MPN Workshop of the Carolinas 2025! 📣 World-renowned faculty speakers discussing the MPN field || #MPNSM South Piedmont AHEC Raajit Rampal, M.D.Ph.D. Ami Patel, MD Elf Lab 🇺🇦🏳️‍🌈🏳️‍⚧️⚧️👊🏾👊🏽🌈🟧 Lucia Masarova, MD southpiedmontahec.org/event/74866

🧵 Clonal Hematopoiesis & Inflammation in BCMA CAR-T Outcomes (MM) 1/ 💉 CAR-T for MM has transformed outcomes, but prolonged cytopenias & secondary myeloid disease (MDS/AML) remain major concerns. This single-center study (n=213) highlights how clonal hematopoiesis (CH) +

2/ 📉 Prolonged cytopenias = worse survival •19% had persistent grade ≥3 cytopenia @ day 100. •Lack of recovery = shorter PFS (15 vs 29 mo) & worse 24-mo OS (55% vs 87%). •64% of these had cytopenias lasting >1 year despite remission. #ICE_T #mmsm #MedEd #myeloma #MedTwitter

3/ 🔥 Inflammation + CH predict recovery •Elevated ferritin ≥300 ng/mL → slower recovery. •CH in 39% (DNMT3A 18%, TP53 12%). •CH + high ferritin = markedly delayed myeloid recovery (HR 0.34, p=.0009). •Distinct pro-inflammatory cytokine profile seen before infusion. #ICE_T

4/ ⚠️ Secondary myeloid disease •9% developed MDS/AML, median 14.5 mo post-CAR-T. •Nearly all linked to expansion of TP53-mutated CH clones. •TP53 VAF ↑ from 3.4% → 44% at disease. •Non-TP53 CH mutations remained stable. #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC

5/ 💀 Outcomes of secondary myeloid disease •Median OS after MDS/AML = 7 mo. •High-risk features common: complex karyotype, monosomy 7/del7q. •Highlights CAR-T’s potential role in accelerating TP53-driven clonal evolution. #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC

6/ 🧪 Translational implications •Pre-CAR-T screening for CH (esp. TP53) + ferritin may guide risk stratification. •High-risk pts need closer monitoring for cytopenias & MDS/AML. •Inflammatory/endothelial signatures = potential therapeutic targets. #ICE_T #mmsm #MedEd

7/ 📌 Bottom line for clinicians •Prolonged cytopenias post-CAR-T = poor outcomes. •TP53 CH + inflammation = red flag for delayed recovery & secondary myeloid disease. •Careful risk-benefit assessment essential before CAR-T in these pts. #ICE_T #mmsm #MedEd #myeloma

How many platelets do I need to perform a safe lumbar puncture in patients with hematologic malignancies? 40 is the new 50! haematologica.org/article/view/1…

Classic Hairy Cell Leukemia With MAP2K1 Mutation: Diagnosis and Targeted Therapy #lymsm |American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/aj…

Our latest publication in #CLML explores #alloHCT outcomes in elderly #myelofibrosis patients Moffitt Cancer Center Muhammad Umair Mushtaq (Abu Mikael) Muhammad Kashif Amin, MD USMIRC News OncoDaily doi.org/10.1016/j.clml…